Advances Aid Treatment, Diagnosis of Celiac Disease

Disorder triggered by gluten in common foods, such as bread, pasta, often goes unnoticed

Related Encyclopedia • Abdominoplasty • Acidophilus • Adhesions • Allergic Rhinitis More... Related Healthscout Videos Nutrition and Cancer Nutrition and Osteoporosis Importance of Good Nutrition Critical Nutrition More... Related Animations • Allergy • GERD • PPI Therapy • What is Cholesterol? More... Related Drug Information • Aciphex • Allegra • Allegra D • Clarinex More... Related News Articles • 9 Genes Are Linked to Alzheimer's • Health Tip: More Than You Can Chew • It Pays to Eat Less as You Age • Brains of Bulimia Patients Wired Differently More...

MONDAY, May 19 (HealthDay News) -- New research could lead to improved diagnosis and treatment of celiac disease, according to studies presented at the Digestive Disease Week meeting in San Diego.

Celiac disease, which affects an estimated one in every 100 Americans, is an autoimmune disorder in the small intestine triggered by a protein called gluten, found in bread, pasta and many other common foods. Celiac disease often goes undiagnosed.

Text Continues Below

---

"At this time, the only effective treatment for celiac disease is a lifelong gluten-free diet, a lifestyle that is difficult for many patients to manage," Dr. Peter H. Green, of the Columbia University Medical School, said in a prepared statement.

"Unfortunately, many people are unaware that they have celiac disease, and if left untreated, it can be life threatening. These studies ... will hopefully lead to improved diagnosis, prevention, treatment and quality of life for this disease," Green said.

In one study, researchers found that an investigational medicine called AT-1001 may protect celiac disease patients from exposure to gluten. The drug does this by preventing gluten from crossing the intestinal mucosa.

While most people with celiac disease do well on a gluten-free diet, inadvertent exposure to gluten is the leading cause of persistent symptoms in adults with celiac disease.

The study of 86 patients found that those who were given gluten and AT-1001 had fewer symptoms of gluten toxicity than those who were given gluten and a placebo. The researchers are now conducting a larger, longer trial.

"Even allowing for the fact that people in clinical trials may practice healthier habits, the fact that all of the groups showed improvement in the first week of the study is significant and helps us to plan better celiac studies," study author Dr. Daniel Leffler, clinical research director at the Celiac Disease Center at Beth Israel Deaconess Medical Center in Boston, said in a prepared statement.

Page:  1 | 2 | Next >>

-- Robert Preidt